Case Series
Late-Onset Posttransplant Lymphoproliferative Disorders after Solid Organ Transplantation in Adults: A Case Series and Review of the Literature
Table 1
Characteristics of each case of PTLD described, including age at diagnosis, type of SOT, time from SOT to PTLD diagnosis, location of PTLD lesions, immunosuppression, histologic subtype, EBV status, treatment, failure of SOT, and patient status (alive or deceased).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SOT: solid organ transplantation; PTLD: posttransplant lymphoproliferative disorder; CNS: central nervous system; ROI: reduction of immunosuppression; R-EPOCH: rituximab, etoposide, prednisone, vincristine, cyclophosphamide, adriamycin; R-GEMOX: rituximab, gemcitabine, oxaliplatin; AVD: adriamycin, vinblastine, dacarbazine. |